Vaxcyte (NASDAQ:PCVX) EVP Sells $1,561,320.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) EVP Jim Wassil sold 18,000 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $86.74, for a total value of $1,561,320.00. Following the sale, the executive vice president directly owned 145,435 shares of the company's stock, valued at $12,615,031.90. The trade was a 11.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

• MarketBeat Week in Review – 4/17 - 4/21

Jim Wassil also recently made the following trade(s):

• On Thursday, October 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.67, for a total transaction of $127,507.50.
• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The stock was sold at an average price of $59.52, for a total transaction of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total value of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total value of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total transaction of $121,185.00.

Vaxcyte Price Performance

---

---

Vaxcyte stock opened at $66.96 on Thursday. Vaxcyte, Inc. has a one year low of $39.87 and a one year high of $90.75. The business has a fifty day moving average price of $59.56 and a 200-day moving average price of $56.49. The firm has a market capitalization of $9.96 billion, a P/E ratio of -8.78 and a beta of 1.23.

• Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter in the previous year, the firm posted ($1.22) EPS. Sell-side analysts expect that Vaxcyte, Inc. will post -8.07 earnings per share for the current fiscal year.

Key Headlines Impacting Vaxcyte

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Vaxcyte reported a positive Phase 3 result for its VAX-31 pneumococcal vaccine candidate in adults. The late-stage win strengthens the program’s regulatory and commercial prospects and prompted bullish commentary that the company had reached a potential “blue-sky” outcome. Vaxcyte leaps on positive Phase III trial of VAX-31
• Positive Sentiment: Analysts remain constructive following the clinical update. Needham assigned Vaxcyte a $122 price target, while BTIG reaffirmed its Buy rating, indicating substantial anticipated upside if VAX-31 continues to advance successfully. Vaxcyte given new price target at Needham
• Positive Sentiment: The company priced a financing consisting of $500 million of common stock and pre-funded warrants plus $500 million of 1.50% convertible senior notes due 2032. The proceeds should provide substantial funding for clinical development and commercialization preparations, while the relatively low coupon limits near-term interest expense. Vaxcyte announces pricing of concurrent offerings
• Neutral Sentiment: Options activity was unusually heavy, with investors purchasing 8,093 put contracts—about 259% of typical volume—suggesting increased hedging or bearish speculation, but not necessarily a change in the company’s fundamentals.
• Negative Sentiment: The equity issuance, pre-funded warrants and potentially convertible notes will increase the share count or create future dilution. The financing was priced at $64 per share, below the stock’s recent trading levels, contributing to selling pressure despite the positive trial news.
• Neutral Sentiment: Chief Accounting Officer Elvia Cowan and EVP Jim Wassil sold 19,000 and 18,000 shares, respectively, under pre-arranged Rule 10b5-1 plans. The transactions reduce their holdings but were scheduled sales and therefore provide limited insight into current management sentiment.

Analysts Set New Price Targets

• Why Investors Are Suddenly Excited About Vaxcyte

PCVX has been the topic of several research analyst reports. Needham & Company LLC upped their price objective on shares of Vaxcyte from $110.00 to $122.00 and gave the stock a "buy" rating in a research report on Monday. Bank of America cut their price objective on Vaxcyte from $133.00 to $130.00 and set a "buy" rating for the company in a report on Monday, September 28th. Wall Street Zen raised Vaxcyte from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. BTIG Research restated a "buy" rating and issued a $89.00 target price on shares of Vaxcyte in a research report on Monday. Finally, Guggenheim boosted their target price on Vaxcyte from $116.00 to $125.00 and gave the stock a "buy" rating in a research report on Monday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Vaxcyte has an average rating of "Moderate Buy" and an average price target of $108.60.

Read Our Latest Stock Report on Vaxcyte

Institutional Trading of Vaxcyte

Institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC increased its holdings in Vaxcyte by 4.0% in the 2nd quarter. Hsbc Holdings PLC now owns 4,151 shares of the company's stock worth $241,000 after acquiring an additional 159 shares in the last quarter. Meeder Advisory Services Inc. lifted its holdings in Vaxcyte by 2.9% during the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company's stock valued at $484,000 after purchasing an additional 231 shares in the last quarter. IFP Advisors Inc boosted its position in shares of Vaxcyte by 72.8% in the second quarter. IFP Advisors Inc now owns 560 shares of the company's stock worth $33,000 after purchasing an additional 236 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of Vaxcyte by 27.6% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,344 shares of the company's stock worth $78,000 after purchasing an additional 291 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of Vaxcyte by 7.0% in the first quarter. Principal Financial Group Inc. now owns 5,275 shares of the company's stock worth $307,000 after purchasing an additional 343 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte's lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.

Featured Stories

• Five stocks we like better than Vaxcyte
• Skydance Just Became a Media Giant—With an $80 Billion Debt Load
• Could Velo3D Be the Next Defense Buyout Target?
• Penguin Solutions Is Soaring as AI Memory Demand Explodes
• Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].